Rybelsus, also known by its generic name, Semaglutide, is a medication that has been primarily designed for the treatment of type 2 diabetes. It is an oral glucagon-like peptide-1 (GLP-1) receptor agonist and works by mimicking the function of the GLP-1 hormone. This hormone is released in the intestines during a meal and helps regulate blood sugar levels.

Rybelsus (generic name: semaglutide) is a medication used for the treatment of type 2 diabetes. Rybelsus 7 mg and Rybelsus 14mg A multinational pharmaceutical company from Denmark called Novo Nordisk produces it.

The weight-loss effects of Rybelsus were becoming increasingly recognized. It helps to slow gastric emptying, reduces appetite, and may influence brain regions that control appetite and energy intake. As a result, it can cause significant weight loss in some people. A study published in "The Lancet" in 2020 demonstrated that individuals who took Semaglutide lost more weight than those who took a placebo. However, the degree of weight loss varies between individuals and depends on various factors, including the dose of Rybelsus 3mg, adherence to a calorie-controlled diet, and regular physical activity.